ProKidney (PROK) News Today $1.65 -0.15 (-8.33%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ProKidney lists Greensboro property for sale, leaving future in city uncertainNovember 19 at 7:03 AM | msn.comFuture of development project promising hundreds of job now uncertainNovember 19 at 2:02 AM | msn.comProKidney lists building where it planned $458M investment for saleNovember 18 at 9:01 PM | bizjournals.comPharma company to expand Broward headquartersNovember 15, 2024 | bizjournals.comProKidney’s Progress in FDA Approval and Financial HealthNovember 13, 2024 | markets.businessinsider.comProKidney’s Future: Balancing Promising FDA Developments with Financial UncertaintiesNovember 13, 2024 | markets.businessinsider.comProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B MeetingNovember 12, 2024 | globenewswire.comTriad's public companies have gained millions in value since electionNovember 12, 2024 | bizjournals.comProKidney (NASDAQ:PROK) Stock, Option ChainNovember 9, 2024 | benzinga.comProKidney: Major Catalyst Is Too Far AwayNovember 7, 2024 | seekingalpha.comProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare ConferenceNovember 5, 2024 | globenewswire.comPower 50 Five to Watch: Bruce Culleton, ProKidneyOctober 23, 2024 | bizjournals.comWe're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn RateOctober 18, 2024 | finance.yahoo.comProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024October 15, 2024 | markets.businessinsider.comProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024October 14, 2024 | globenewswire.comProKidney to Participate in the UBS Virtual Organ Restoration DayOctober 9, 2024 | globenewswire.comProKidney (NASDAQ:PROK) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comJP Morgan Initiates Coverage of ProKidney (PROK) with Neutral RecommendationOctober 1, 2024 | msn.comMaintaining Hold on ProKidney: Balancing Potential Against Need for Further Efficacy DataSeptember 30, 2024 | markets.businessinsider.comProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. started coverage on shares of ProKidney in a research report on Monday. They issued a "neutral" rating for the company.September 30, 2024 | marketbeat.comGlobal Corporate Wellness Market to Surpass ~USD 117 Billion by 2030 | DelveInsightSeptember 23, 2024 | finance.yahoo.comArch Biopartners Inc. (ARCH.V) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comInsider Selling: ProKidney Corp. (NASDAQ:PROK) Insider Sells 16,412 Shares of StockSeptember 21, 2024 | insidertrades.comProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 SharesProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Darin J. Weber sold 16,412 shares of the company's stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $2.50, for a total transaction of $41,030.00. Following the completion of the transaction, the insider now owns 103,480 shares in the company, valued at approximately $258,700. The sale was disclosed in a legal filing with the SEC, which is available through this link.September 20, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Down 6.7%ProKidney (NASDAQ:PROK) Stock Price Down 6.7%September 20, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Down 3.3% ProKidney (NASDAQ:PROK) Shares Down 3.3%September 12, 2024 | marketbeat.comBuy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease TreatmentSeptember 11, 2024 | markets.businessinsider.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.39ProKidney (NASDAQ:PROK) Shares Gap Up to $2.39September 10, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Earns Buy Rating from Analysts at GuggenheimGuggenheim assumed coverage on ProKidney in a research report on Tuesday. They issued a "buy" rating and a $6.00 price objective for the company.September 10, 2024 | marketbeat.comMaintaining Hold on ProKidney Amid Strategic Shifts and Regulatory UncertaintiesSeptember 5, 2024 | markets.businessinsider.comProKidney’s Hold Rating Maintained Amid Financing and Clinical UncertaintiesSeptember 5, 2024 | markets.businessinsider.comProKidney drops Phase III CKD study to focus on US market and save up to $175mSeptember 5, 2024 | finance.yahoo.comProKidney (NASDAQ:PROK) Stock Price Up 6%ProKidney (NASDAQ:PROK) Shares Up 6%September 5, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Gap Down After Analyst DowngradeProKidney (NASDAQ:PROK) Shares Gap Down Following Analyst DowngradeSeptember 4, 2024 | marketbeat.comBank of America Trims ProKidney (NASDAQ:PROK) Target Price to $3.00Bank of America dropped their price target on shares of ProKidney from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Wednesday.September 4, 2024 | marketbeat.comProKidney Reports Strategic Updates To Phase 3 Study Of Rilparencel; To Discontinue PROACT 2 StudySeptember 4, 2024 | markets.businessinsider.comProKidney revises Phase 3 program for lead assetSeptember 3, 2024 | msn.comProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.September 3, 2024 | globenewswire.comProKidney (NASDAQ:PROK) Trading Down 5.9%ProKidney (NASDAQ:PROK) Trading Down 5.9%August 27, 2024 | marketbeat.comProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 27, 2024 | globenewswire.comProKidney (NASDAQ:PROK) Shares Up 8.3%ProKidney (NASDAQ:PROK) Trading 8.3% HigherAugust 23, 2024 | marketbeat.comThe Prognosis For ProKidney: UnclearAugust 23, 2024 | seekingalpha.comVanguard Group Inc. Sells 1,085,965 Shares of ProKidney Corp. (NASDAQ:PROK)Vanguard Group Inc. reduced its holdings in ProKidney Corp. (NASDAQ:PROK - Free Report) by 37.5% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,813,079 shares of the company's stock after selling 1,085,965 shares durAugust 19, 2024 | marketbeat.comProKidney resumes manufacturing and Phase 3 clinicals, extends cash runwayAugust 16, 2024 | bizjournals.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.18ProKidney (NASDAQ:PROK) Shares Gap Up to $2.18August 12, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading 6.2% Higher ProKidney (NASDAQ:PROK) Stock Price Up 6.2%August 9, 2024 | marketbeat.comProKidney Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 9, 2024 | globenewswire.comProKidney (NASDAQ:PROK) Trading Down 5.5%ProKidney (NASDAQ:PROK) Shares Down 5.5%July 30, 2024 | marketbeat.comProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutionsJuly 30, 2024 | finance.yahoo.comChronic Kidney Disease for Seven Major Markets: US, France, Germany, Italy, Spain, UK, Japan Drug Forecasts and Analysis 2023-2033July 25, 2024 | finance.yahoo.com Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW PROK Media Mentions By Week PROK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PROK News Sentiment▼0.670.45▲Average Medical News Sentiment PROK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PROK Articles This Week▼42▲PROK Articles Average Week Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKLI News CNTA News EVO News HRMY News IRON News NAMS News TARS News RXRX News GLPG News XNCR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PROK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PROK Stock Alerts